Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study | Synapse
February 9, 2024Open Access
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with